medicalxpress.com· Medical Xpress - Cancer·· 20 hours agoPickScore93
New targeted therapy improved survival for patients with KRAS-mutated lung cancer
In brief
Divarasib extended survival in previously treated KRAS G12C-mutant NSCLC in the Phase III Krascendo 1 trial, with median OS of 17.7 months versus 12 months in the control arm. The MD Anderson Cancer Center team enrolled 338 patients; compared with sotorasib or adagrasib, divarasib reduced the risk of disease progression by 42% and death by 44%, with median PFS of 9.8 versus 5.7 months and ORR of 58.4% versus 32.3%.
Why it matters
Head-to-head Phase III data provide OS, PFS, ORR and tolerability results directly compared with approved KRAS G12C inhibitors.
Source: medicalxpress.com · medicalxpress.com